We report the presence of drug resistance mutations in 7.4% (2/27) of the treatment-naive, HIV-1-infected children in Pune, India, who had HIV-1 RNA levels >1,000 copies/ml. Nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations, namely A98G and K103N, were observed in two separate sequences. In addition, three study sequences displayed three separate HIV-1 protease minor resistance mutations—L10I, A71T, and T74S. These preliminary data from Pune, India, reporting the presence of HIVDR in treatment-naive, HIV-1-infected children, reinforces the need to conduct large-scale studies to assess the prevalence of primary HIVDR in the pediatric population, which in turn will aid in planning protocols and policies related to antiretroviral treatment for the pediatric population.
Get full access to this article
View all access options for this article.
References
1.
BecquetR, EkoueviDK, ArriveE, StringerJS, MedaN, ChaixML, et al.: Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis, 2009; 49(12):1936–1945.
2.
UNAIDS/WHO: Paediatric HIV surveillance among infants and children less than 18 years of age. World Health Organization 2013. Available at http://apps.who.int/iris/bitstream/10665/85513/1/9789241505833_eng.pdf. Accessed on August22, 2013.
3.
DeshpandeA, RecordonP, DeshmukhR, FaureM, JauvinV, GarrigueI, et al.: Molecular characterization of HIV type 1 isolates from unrelated patients of Mumbai (Bombay) India: A detection of rare resistance mutations. AIDS Res Hum Retroviruses, 2004; 20:1032–1035.
4.
BalakrishnanP, KumaraswamyN, KantorR, SolomonS, VidyaS, MayerKH, et al.: HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses, 2005; 21(4):301–305.
5.
SenS, TripathySP, ChimanpureVM, PatilAA, BagulRD, and ParanjapeRS: Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment naïve and treatment experienced patients from Pune, India. AIDS Res Hum Retroviruses, 2007; 23(4):489–497.
6.
SenS, TripathySP, PatilAA, ChimanpureVM, and ParanjapeRS: High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment experienced patients from Pune, India. AIDS Res Hum Retroviruses, 2007; 23(10):1303–1308.
7.
LallM, GuptaRM, SenS, KapilaK, TripathiSP, and ParanjapeRS: Profile of primary resistance in HIV-1 infected treatment naïve individuals from Western India. AIDS Res Hum Retroviruses, 2008; 24(7):987–990.
8.
TamuraK, PetersonD, PetersonN, StecherG, NeiM, and KumarS: MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol, 2011; 28:2731–2739.
9.
FerreiraFG, PintoJA, KakehasiFM, CletoS, TupinambásU, AleixoAW, et al.: Prevalence of primary drug resistance-associated mutations among HIV Type 1 vertically infected children in Belo Horizonte, Brazil. AIDS Res Hum Retroviruses, 2010; 26(2):229–232.
10.
CaneP, ChrystieI, DunnD, EvansB, GerettiAM, GreenH, et al.: Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ, 2005; 331:7529.
11.
WensingAM, van de VijverDA, AngaranoG, AsjöB, BalottaC, BoeriE, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis, 2005; 192(6):958–966.
12.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed on August16, 2013.
13.
Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed on August16, 2013.
14.
PersaudD, PalumboP, ZiemniakV, ChenJ, RaySC, HughesM, et al.: Early archiving and predominance of non nucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis, 2007; 195(10):1402–1410.
15.
ChakrabortyR, SmithCJ, DunnD, GreenH, DuongT, DoerholtK, et al.: HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J, 2008; 27(5):457–459.
16.
PedrosoC, QueirozATL, AlcantaraLC, DrexlerJF, DiazRS, WeyllN, et al.: High prevalence of primary antiretroviral resistance among HIV-1-infected adults and children in Bahia, a northeast state of Brazil. J Acquir Immune Defic Syndr, 2007; 45(2):251–253.
17.
Soto-RamirezLE, Rodriguez-DiazR, HarrisDR, and HazraR: HIV drug resistance-associated mutations in antiretroviral naïve HIV-1-infected Latin American children. Adv Virol, 2010; 2010:407476.
18.
KurleS, GangakhedkarRR, SenS, HayatnagarkarSS, TripathySP, and ParanjapeRS: Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV Type 1 subtype C-infected infants in India. AIDS Res Hum Retroviruses, 2007:23(5):682–685.
19.
MoorthyA, GuptaA, BhosaleR, TripathyS, SastryJ, KulkarniS, et al.: Nevirapine resistance and breast-milk HIV transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One, 2009; 4(1):e4096.
20.
SoundararajanL, KarunaianandhamR, JauvinV, SchriveMH, RamachandranR, NarayananPR, et al.: Characterization of HIV-1 isolates from antiretroviral drug-naïve children in southern India. AIDS Res Hum Retroviruses, 2007; 23(9):1119–1126.
